BioRestorative Therapies, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioRestorative Therapies, Inc. engages in the development and commercialization of advanced stem cell-based therapeutic products and biologics, focused primarily on addressing degenerative disc disease, metabolic disorders, and aesthetic medicine. Its core offerings include autologous bone marrow-derived mesenchymal stem cell therapies such as BRTX-100 for treating chronic lower back pain and chronic cervical discogenic pain; allogeneic brown adipose-derived stem cell products targeting metabolic diseases including obesity, type 2 diabetes, and polycystic ovary syndrome; and secretome-based biologics consisting of exosomes, growth factors, and cytokines for cosmetic applications. The company also provides contract manufacturing and research services leveraging its cell biology and biologics production capabilities. Founded in 1997, it is headquartered in Melville, New York, and operates primarily in the United States. Recent major developments include the FDA clearance of the Investigational New Drug application for BRTX-100 to treat chronic cervical discogenic pain, expanding its clinical pipeline beyond chronic lower back pain. BioRestorative has commenced Phase 2 clinical trials for BRTX-100 addressing chronic lumbar disc disease with positive safety and efficacy results, targeting an accelerated Phase 3 and Biologics License Application (BLA) submission. The company entered a strategic supply agreement with Evolutionary Biologics to manufacture biologic cosmetic products for the fast-growing aesthetics market, leveraging its ISO-7 certified cleanroom manufacturing facility. Additionally, BioRestorative launched a $2 million stock repurchase program and raised $1.085 million via a registered offering to support strategic growth initiatives. It is expanding commercial offerings in the emerging bio-cosmeceuticals sector through IND-enabling studies aimed at pioneering FDA-approved cell-based aesthetic therapeutics. BioRestorative operates within the regenerative medicine and biotechnology industries and targets healthcare providers, medical spas, dermatologists, and plastic surgeons primarily in the US market. Its therapeutic development emphasizes chronic and degenerative conditions with a robust clinical pipeline supported by proprietary cell and biologics manufacturing technologies. The company maintains a strong financial position with no debt and a focus on sustainable growth through clinical advancement and strategic commercial partnerships.
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Below Fifty Day Moving Average – Here’s Why
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs